Skye Bioscience, Inc. (SKYE) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Skye Bioscience to discontinue development of eye disease treatment
Skye Bioscience said on Monday it intends to discontinue development of its experimental eye disease treatment after it failed in a mid-stage study.
